Apeloa Pharmaceutical's Pentoxifylline Extended-Release Tablets Secure Official Drug Approval

Stock News08-10

Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) announced that its controlling subsidiary, Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd., has received a Drug Registration Certificate from the National Medical Products Administration for its pentoxifylline extended-release tablets.

Pentoxifylline extended-release tablets are classified as peripheral vasodilators, used to treat peripheral vascular disorders including intermittent claudication and rest pain.

According to relevant market data, the domestic market size for pentoxifylline extended-release tablets in 2025 is estimated at approximately 52.27 million tablets, with total sales revenue of around 262 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment